Search

Search Constraints

You searched for: Author/Creator Tu, Hai-Yan

Search Results

1. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. (December 2017)

2. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases. (May 2019)

3. Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. (June 2021)

4. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. (November 2018)

5. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. (September 2021)

6. Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66–73]. (December 2021)

7. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. (2nd November 2017)

8. Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study. (December 2020)

9. Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome Sequencing. Issue 10 (20th October 2015)

10. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). (February 2021)